Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma
M. Vanden Bempt, K. Debackere, S. Demeyer, Q. Van Thillo, N. Meeuws, S. Provost, N. Mentens, K. Jacobs, O. Gielen, D. Nittner, S. Ogawa, K. Kataoka, C. Graux, T. Tousseyn, J. Cools, D. Dierickx
The paper identifies MYCN overexpression in PTCL and shows EZH2 as a transcriptional co-factor for MYCN-driven gene activation, with therapeutic implications for HDAC inhibitors.
bioRxiv · Mar 31, 2022Cancer Biology